Tumor necrosis factor inhibitors (anti-TNFs) are widely used therapies for the treatment of
inflammatory bowel diseases (IBD); however, their administration is not risk-free. Heart …

Background Prescribing information for tumor necrosis factor alpha (TNFα) inhibitors, a
mainstay of treatment for moderate to severe inflammatory bowel disease (IBD), instructs …

The use of tumor necrosis factor alpha inhibitors anti-TNFa (infliximab, adalimumab, and
certolizumab) in the treatment of inflammatory bowel disease (IBD) provide a major …

BACKGROUND Anti-tumor necrosis factor agents were the first biologic therapy approved
for the management of Crohn's disease (CD). Heart failure (HF) is a rare but potential …

Objective Heart failure (HF) exerts deleterious effects on the gastrointestinal tract and the gut
microbiome, yet its impact on inflammatory bowel disease (IBD) is unknown. This study was …

There are several adverse events that can occur in the setting of tumor necrosis factor-α
inhibitor treatment for inflammatory bowel disease. The most common side effects include …

Purpose To assess safety and effectiveness of anti-tumor necrosis factor (anti-TNF) therapy
in IBD patients≥ 60 years. Methods Ninety IBD patients≥ 60 years at initiation of anti-TNF …

Anti-tumor necrosis factor (anti-TNF) agents are widely used in the management of the
inflammatory bowel diseases (IBDs), Crohn's disease (CD), and ulcerative colitis (UC), when …

Background and aims Inflammatory bases lead to a simultaneous flourishing of
cardiovascular complications with inflammatory bowel disease (IBD). As a released …

DISCUSSION The association between TNF-α and congestive heart failure (CHF) has been
long established. Tumor necrosis factor alpha contributes to CHF progression through …